The immunosuppressant FTY720 prolongs survival in a mouse model of diet-induced coronary atherosclerosis and myocardial infarction

Journal of Cardiovascular Pharmacology

Volumn 63, Issue 2, 2014, Pages 132-143

  Wang, Guanying ^a,b   Kim, Roy Y ^a   Imhof, Isabella ^a,b   Honbo, Norman ^a,b   Luk, Fu S ^a   Li, Kang ^a   Kumar, Nikit ^a   Zhu, Bo Qing ^a,b   Eberlé, Delphine ^a   Ching, Daniel ^a   Karliner, Joel S ^a,b   Raffai, Robert L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ApoE; Cardioprotection; Coronary atherosclerosis; FTY720; Heart failure; Immunosuppression; S1P

Indexed keywords

ANIMALS; APOLIPOPROTEINS E; CARDIOTONIC AGENTS; CORONARY ARTERY DISEASE; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; PROPYLENE GLYCOLS; SPHINGOSINE; SURVIVAL RATE; T-LYMPHOCYTES, REGULATORY; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA; VENTRICULAR FUNCTION, LEFT;

EID: 84894174363     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000031     Document Type: Article

References (46)

1. Kimura T, Sato K, Kuwabara A, et al. Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J Biol Chem. 2001;276:31780-31785
2. Zhang J, Honbo N, Goetzl EJ, et al. Signals from type 1 sphingosine 1-phosphate receptors enhance adult mouse cardiac myocyte survival during hypoxia. Am J Physiol Heart Circ Physiol. 2007;293:H3150-H3158
3. Rosen H, Goetzl EJ. Sphingosine 1-phosphate and its receptors: An autocrine and paracrine network. Nat Rev Immunol. 2005;5:560-570
4. Means CK, Xiao CY, Li Z, et al. Sphingosine 1-phosphate S1P2 and S1P3 receptor-mediated Akt activation protects against in vivo myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2007; 292:H2944-H2951
5. Jin ZQ, Karliner JS, Vessey DA. Ischaemic postconditioning protects isolated mouse hearts against ischaemia/reperfusion injury via sphingosine kinase isoform-1 activation. Cardiovasc Res. 2008;79:134-140
6. Jin ZQ, Zhang J, Huang Y, et al. A sphingosine kinase 1 mutation sensitizes the myocardium to ischemia/reperfusion injury. Cardiovasc Res. 2007;76:41-50
7. Sattler K, Levkau B. Sphingosine-1-phosphate as a mediator of highdensity lipoprotein effects in cardiovascular protection. Cardiovasc Res. 2009;82:201-211
8. Vessey DA, Kelley M, Li L, et al. Role of sphingosine kinase activity in protection of heart against ischemia reperfusion injury. Med Sci Monit. 2006;12:BR318-BR324
9. Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: Mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther. 2007;115:84-105
10. Tao R, Hoover HE, Zhang J, et al. Cardiomyocyte S1P1 receptormediated extracellular signal-related kinase signaling and desensitization. J Cardiovasc Pharmacol. 2009;53:486-494
11. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: Targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res. 2004;61:448-460
12. Lacerda L, Somers S, Opie LH, et al. Ischaemic postconditioning protects against reperfusion injury via the SAFE pathway. Cardiovasc Res. 2009; 84:201-208
13. Vessey DA, Li L, Honbo N, et al. Sphingosine 1-phosphate is an important endogenous cardioprotectant released by ischemic pre- and postconditioning. Am J Physiol Heart Circ Physiol. 2009;297:H1429-H1435
14. Egom EE, Ke Y, Musa H, et al. FTY720 prevents ischemia/reperfusion injury-Associated arrhythmias in an ex vivo rat heart model via activation of Pak1/Akt signaling. J Mol Cell Cardiol. 2010;48:406-414
15. Hofmann U, Burkard N, Vogt C, et al. Protective effects of sphingosine-1-phosphate receptor agonist treatment after myocardial ischaemia-reperfusion. Cardiovasc Res. 2009;83:285-293
16. Hla T, Brinkmann V. Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation. Neurology. 2011;76:S3-S8
17. Chiba K. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Pharmacol Ther. 2005; 108:308-319
18. Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 2004;427:355-360
19. Keul P, Tolle M, Lucke S, et al. The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2007;27:607-613
20. Nofer JR, Bot M, Brodde M, et al. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation. 2007;115:501-508
21. Raffaï RL, Weisgraber KH. Hypomorphic apolipoprotein E mice. A new model of conditional gene repair to examine apolipoprotein E-mediated metabolism. J Biol Chem. 2002;277:11064-11068
22. Raffai RL, Loeb SM, Weisgraber KH. Apolipoprotein E promotes the regression of atherosclerosis independently of lowering plasma cholesterol levels. Arterioscler Thromb Vasc Biol. 2005;25:436-441
23. Zhang S, Picard MH, Vasile E, et al. Diet-induced occlusive coronary atherosclerosis, myocardial infarction, cardiac dysfunction, and premature death in Scavenger receptor class B type I-deficient, hypomorphic apolipoprotein ER61 mice. Circulation. 2005;111:3457-3464
24. McManus DD, Shah SJ, Fabi MR, et al. Prognostic value of left ventricular end-systolic volume index as a predictor of heart failure hospitalization in stable coronary artery disease: Data from the Heart and Soul Study. J Am Soc Echocardiogr. 2009;22:190-197
25. Belkaid Y, Rouse BT. Natural regulatory T cells in infectious disease. Nat Immunol. 2005;6:353-360
26. Hasegawa Y, Suzuki H, Sozen T, et al. Activation of sphingosine 1-phosphate receptor-1 by FTY720 is neuroprotective after ischemic stroke in rats. Stroke. 2010;41:368-374
27. Wei Y, Yemisci M, Kim HH, et al. Fingolimod provides long-Term protection in rodent models of cerebral ischemia. Ann Neurol. 2011;69: 119-129
28. Man K, Ng KT, Lee TK, et al. FTY720 attenuates hepatic ischemiareperfusion injury in normal and cirrhotic livers. Am J Transplant. 2005;5:40-49
29. Awad AS, Ye H, Huang L, et al. Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney. Am J Physiol Renal Physiol. 2006;290:F1516-F1524
30. Egom EE, Mohamed TM, Mamas MA, et al. Activation of Pak1/Akt/ eNOS signaling following sphingosine-1-phosphate release as part of a mechanism protecting cardiomyocytes against ischemic cell injury. Am J Physiol Heart Circ Physiol. 2011;301:H1487-H1495
31. Liu W, Zi M, Naumann R, et al. Pak1 as a novel therapeutic target for antihypertrophic treatment in the heart. Circulation. 2011;124: 2702-2715
32. Hofmann U, Hu K, Walter F, et al. Pharmacological pre- and postconditioning with the sphingosine-1-phosphate receptor modulator FTY720 after myocardial ischaemia-reperfusion. Br J Pharmacol. 2010;160:1243-1251
33. Blom T, Back N, Mutka AL, et al. FTY720 stimulates 27-hydroxycholesterol production and confers atheroprotective effects in human primary macrophages. Circ Res. 2010;106:720-729
34. Raffaï RL, Dong L-M, Farese RV Jr, et al. Introduction of human apolipoprotein E4 domain interaction into mouse apolipoprotein E. Proc Natl Acad Sci USA. 2001;98:11587-11591
35. Klingenberg R, Nofer JR, Rudling M, et al. Sphingosine-1-phosphate analogue FTY720 causes lymphocyte redistribution and hypercholesterolemia in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 2007;27: 2392-2399
36. Poti F, Costa S, Bergonzini V, et al. Effect of sphingosine 1-phosphate (S1P) receptor agonists FTY720 and CYM5442 on atherosclerosis development in LDL receptor deficient (LDL-R(-)/(-)) mice. Vascul Pharmacol. 2012;57:56-64
37. Panizzi P, Swirski FK, Figueiredo JL, et al. Impaired infarct healing in atherosclerotic mice with Ly-6C(hi) monocytosis. J Am Coll Cardiol. 2010;55:1629-1638
38. Swirski FK, Libby P, Aikawa E, et al. Ly-6Chi monocytes dominate hypercholesterolemia-Associated monocytosis and give rise to macrophages in atheromata. J Clin Invest. 2007;117:195-205
39. Ioannou A, Dalle Lucca J, Tsokos GC. Immunopathogenesis of ischemia/reperfusion-Associated tissue damage. Clin Immunol. 2011; 141:3-14
40. Yang Z, Day YJ, Toufektsian MC, et al. Myocardial infarct-sparing effect of adenosine A2A receptor activation is due to its action on CD4+ T lymphocytes. Circulation. 2006;114:2056-2064
41. Burne-Taney MJ, Ascon DB, Daniels F, et al. B cell deficiency confers protection from renal ischemia reperfusion injury. J Immunol. 2003;171: 3210-3215
42. Yeh CC, Li H, Malhotra D, et al. Sphingolipid signaling and treatment during remodeling of the uninfarcted ventricular wall after myocardial infarction. Am J Physiol Heart Circ Physiol. 2009;296:H1193-H1199
43. Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol. 2010;11:7-13
44. Hofmann U, Beyersdorf N, Weirather J, et al. Activation of CD4+ T lymphocytes improves wound healing and survival after experimental myocardial infarction in mice. Circulation. 2012;125:1652-1663
45. Daniel C, Sartory N, Zahn N, et al. FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+CD25+ regulatory T cells. J Immunol. 2007;178:2458-2468
46. Eberle D, Luk FS, Kim RY, et al. Inducible Apoe gene repair in hypomorphic ApoE mice deficient in the low-density lipoprotein receptor promotes atheroma stabilization with a human-like lipoprotein profile. Arterioscler Thromb Vasc Biol. 2013;33:1759-1767